IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Maurice Winn who wrote (1509)	3/9/1998 11:51:00 AM
From: Pseudo Biologist	Read Replies (1) of 1762

Maurice, thanks for the information. The idea of getting the patient's own immune system, or components thereof, to fight the cancer cells is quite attractive and has been pursued for quite some time. I'll try to take a look at the Malaghan approach in more detail to see if I can figure out what is new about it. Rituxan, to some degree, may be argued to act as a trigger to induce the immune system to get rid of CD20+ cells. At least this is one of the mechanisms by which it is supposed to work. Oncolym, Y2B8 and Bexxar take a more direct, some may say brute force, approach by nuking the lymphoma cells at short range. The report of tuberculosis arising from use of Rituxan makes remote sense, but I cannot see this as a general occurrence - would surprise me. PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next